Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | AHR | P35869 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21494511 | 0.73 | KDM4E (0.40) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL18698190 | 0.73 | KDM4E (0.40) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL18698083 | 0.69 | KDM4E (0.36) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL19298989 | 0.69 | KDM4E (0.36) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2244453 | 0.68 | TAAR1 (0.40) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2085647 | 0.68 | MAOA (0.59) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL22537996 | 0.67 | KDM4E (0.34) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL21315933 | 0.65 | ALDH1A1 (0.36) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL23589780 | 0.65 | KDM4E (0.33) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL23628355 | 0.65 | HSD17B10 (0.32) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524704-B2 | Azepinoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8466143-B2 | Azepine derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8133992-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100173824-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595311-B2 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | EXELIXIS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-7485634-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070015746-A1 | Azepine derivaties as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1532153-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099821-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | HTR5A, MTNR1A, PTGDR | KDM4E 4534/4885ALDH1A1 1722/4885MAPT 2587/4885 |
| US-20100173824-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | HTR2A, HTR5A, HTR2C | KDM4E 4561/4885ALDH1A1 1321/4885MAPT 2665/4885 |
| US-20070015746-A1 | Azepine derivaties as pharmaceutical agents | HTR5A, TACR2, TACR1 | KDM4E 2539/4885ALDH1A1 933/4885MAPT 2845/4885 |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | HTR5A, MTNR1A, PTGDR | KDM4E 4534/4885ALDH1A1 1722/4885MAPT 2587/4885 |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | KDM4E 3410/4885ALDH1A1 622/4885MAPT 4460/4885 |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | KDM4E 4581/4885ALDH1A1 3963/4885MAPT 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.